In a recent paper, Perez-Pozo et al. 1 concluded that high doses of fructose raise blood pressure and cause features of metabolic syndrome, and that fructose may therefore have a role in the current epidemics of obesity and diabetes. Their conclusion is poorly supported and should not be used to inform the public debate on fructose for three reasons. First, the study is weakened through lack of a rigorous double-blind experimental design. That investigators and staff knew throughout the study which participants were receiving allopurinol makes it impossible to rule out the prospect of subjective bias from experimental subjects, analysts and study principals.
Second, the experimental design lacked a proper control. The authors administered fructose±allopurinol to human subjects to test the hypothesis that excessive fructose intake can induce the features of metabolic syndrome and that the induction is reversible. Their failure to provide an appropriate non-fructose comparison group invalidates all conclusions about fructose.
Third, the amount of dietary þ supplementary fructose in experimental diets (55 g þ 200 g ¼ 34% of the total energy) is nearly quadruple the mean (9.1% of the total energy) and double the 95th percentile (o18% of the total energy) human fructose intakes recently established by Marriott et al. 2 Such macronutrient excess is atypical of the human fructose experienceFcharacterized instead by moderate fructose intake in the presence of equivalent amounts of glucoseFand further diminishes the clinical relevance of this study.
Thus, the conclusion by Perez-Pozo et al. that excessive fructose consumption could have a causal role in the metabolic syndrome is inadequately supported by the current work. The weak experimental design fails to demonstrate a unique role for fructose vis-à-vis other nutritive sugars, lacks a suitable control, is not doubleblinded and relies on exaggerated fructose exposures. It would be inappropriate to use this study to inform the public debate on fructose.
